Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Circ Heart Fail. 2014 May 29;7(4):627–633. doi: 10.1161/CIRCHEARTFAILURE.114.001129

Table 1.

Potent anti-arrhythmic effect of ranolazine (5 μM) in coronary-perfused canine right atrial preparations isolated from dogs with heart failure

AF/AFl incidence AF/AFl duration (sec) Vulnerable window (ms)
Control 10/17 atria 109±178 36±23
Ranolazine 3/10 atria 4.0±4.3* 13±6

The longest atrial fibrillation/atrial flutter (AF/AFl) episode recorded in each atrium was taken for calculation of AF/AFl duration.

*

P<0.05 vs. control (paired t-test, three atria that develop AF both before and after ranolazine).